News
Presented 24-week topline results from the Phase 2 VERONA study in DME at the Retina World Congress in May 2025, highlighting DURAVYU’s potential to transform the treatment landscape in DME, the ...
Fidelis Insurance Holdings Limited (NYSE:FIHL) ("Fidelis Insurance Group" or "the Company"), a global specialty insurer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback